Quinolones in dermatology

Clinics in Dermatology

Volumn 21, Issue 1, 2003, Pages 56-63

  Sable, David ^a   Murakawa, George J ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CAFFEINE; CALCIUM ION; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; CYCLOSPORIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; ENOXACIN; FENBUFEN; FLEROXACIN; GATIFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MAGNESIUM ION; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; RIFAMPICIN; ROSOXACIN; SPARFLOXACIN; SULTAMICILLIN; THEOPHYLLINE; TROVAFLOXACIN; WARFARIN;

ABDOMINAL PAIN; ANTHRAX; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL; BACTERIAL INFECTION; BINDING AFFINITY; BIOAVAILABILITY; BIOLOGICAL WARFARE; BONE INFECTION; CELL DEATH; CELLULITIS; DIABETIC FOOT; DIARRHEA; DNA CLEAVAGE; DNA REPLICATION; DNA SYNTHESIS INHIBITION; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PENETRATION; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DRUG URINE LEVEL; GASTROENTERITIS; GASTROINTESTINAL INFECTION; GONORRHEA; GRANULOMA INGUINALE; HALLUCINATION; HEADACHE; HUMAN; LONG TERM CARE; MYCOPLASMA; NAUSEA; OSTEOMYELITIS; PRIORITY JOURNAL; PROSTATITIS; PUNCTURE; PYODERMA; RESPIRATORY TRACT INFECTION; RNA SYNTHESIS; SEIZURE; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SKIN DISEASE; SOFT TISSUE INFECTION; URETHRITIS; URINARY TRACT INFECTION; VOMITING; WOUND; WOUND INFECTION;

EID: 0037214754     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(02)00322-X     Document Type: Article

References (74)

1. Lescher G.Y., Froelich E.D., Gruet M.D., et al. 1-8 naphthyridine derivatives. A new class of chemotherapeutic agents. J Med Pharmaceut Chem. 5:1962;1063-1068.
2. Appelbaum P.C., Hunter P.A. The fluoroquinolone antibacterials past, present and future perspectives . Int J Antimicrob Agents. 16:2000;5-15.
3. Park G.B., Saneski J., Weng T., Edelson J. Pharmacokinetics of rosoxacin in human volunteers. J Pharm Sci. 71:1982;461-462.
4. Gellert M., Mizuuchi K., O'Dea M.H., et al. DNA gyrase an enzyme that introduces superhelical turns in DNA . Proc Natl Acad Sci USA. 73:1976;3872-3876.
5. Hane M.W., Wood T.H. Escherichia coli K-12 mutants resistant to nalidixic acid genetic mapping and dominance studies . J Bacteriol. 99:1969;238-241.
6. Nakamura S., Nakamura M., Kojima T., et al. gyrA and gyrB mutations in quinolone resistant strains of Escherichia coli. Antimicrob Agents Chemother. 33:1989;254-255.
7. Kato J.I., Nishimura Y.I., Imamura R., et al. New topoisomerase essential for chromosome segregation in E. coli. Cell. 63:1990;393-404.
8. Levine C., Hiasa H., Marians K.J. DNA gyrase and topoisomerase IV biochemical activities, physiological roles during chromosome replication, and drug sensitivities . Biochim Biophys Acta. 140:1998;29-43.
9. Blanche F., Cameron B., Bernard F.X., et al. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob Agents Chemother. 40:1996;2714-2720.
10. Hooper D.C. Mode of action of fluoroquinolones. Drugs. 58:(Suppl 2):1999;6-10.
11. Hooper D.C. Mechanisms of quinolone resistance. Drug Resistance Updates. 2:1999;38-55.
12. Pan X.S., Fisher L.M. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob Agents Chemother. 42:1998;2810-2816.
13. Shen L.L., Kohl-Brenner W.E., Weigl D., et al. Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding in enzyme - DNA complexes. J Biol Chem. 264:1989;2973-2978.
14. Drlica K., Zhoa X.L. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Rev. 61:1997;377-392.
15. Critchlow S.E., Maxwell A. DNA cleavage is not required for the binding of quinolone drugs to the DNA gyrase-DNA complex. Biochemistry. 35:1996;7387-7393.
16. Khodursky A.B., Cozzarelli N.R. The mechanism of inhibition of topoisomerase IV by quinolone antibiotics. J Biol Chem. 273:1998;2768-2777.
17. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs. 58:(Suppl 2):1999;29-36.
18. Bergan T. Pharmacokinetics of the fluoroquinolones. In vitro properties of the quinolones. Andriole V.T. The quinolones. 2nd ed: 1998;143-182 Academic Press, San Diego.
19. Gilbert D.N., Moellering R.C., Sande M.A. The Sanford guide to antimicrobial therapy. 31st Ed: 2001.
20. Andriole V.T. The future of the quinolones. Drugs. 58:(Suppl 2):1999;1-5.
21. Sadick N.S. Systemic antimicrobial agents. Wolverton S.E. Comprehensive dermatologic drug therapy. 2001;39-40 WB Saunders, Philadelphia.
22. Dupont H.L., Ericsson C.D. Prevention and treatment of travelers' diarrhea. N Engl J Med. 328:1993;1821-1827.
23. Murphy G.S., Bodhidatta L., Echeverria P., et al. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann Intern Med. 118:1993;582-586.
24. Graninger W., Zedtwitz-Liebenstein K., Laferl H., Burgmann H. Quinolones in gastrointestinal infections. Chemotherapy. 42:1996;43-53.
25. Ball P. Future of the quinolones. Semin Respir Infect. 16:2001;215-224.
26. Wolfson J.S., Hooper D.C. Treatment of genitourinary tract infections with fluoroquinolones activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis . Antimicrob Agents Chemother. 33:1989;1655-1661.
27. Schaeffer A.J., Darras F.S. The efficacy of norfloxacin in the treatment of chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin. J Urol. 144:1990;690-693.
28. Parish L.C., Jungkind D.L. Systemic antimicrobial therapy for skin and skin structure infections comparison of fleroxacin and ceftazidime . Am J Med. 94:1993;166S-173S.
29. Parish L.C., Witkowski J.A., Routh H.B. Moxifloxacin (Aveleox) for the treatment of bacterial skin infections. Skin Therapy Lett. 6:2001;1-2.
30. Nichols R.L., Smith J.W., Gentry L.O., et al. Multicenter randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections. South Med J. 90:1997;1193-2000.
31. Karchmer A.W. Fluoroquinolone treatment of skin and skin structure infections. Drugs. (Suppl 2):1999;82-84.
32. Beam T.R.J., Gutierrez I., Powell S., et al. Prospective study of the efficacy and safety of oral and intravenous ciprofloxacin in the treatment of diabetic foot infections. Rev Infect Dis. 11:(Suppl 5):1989;S1163.
33. Lipsky B.A., Baker P.D., Landon G.C., et al. Antibiotic therapy for diabetic foot infections comparison of two parenteral-to-oral regimens . Clin Infect Dis. 24:1997;643-648.
34. Barnberger D.M., Daus G.P., Gerding D.N. Osteomyelitis in the feet of diabetic patients long-term results, prognostic factors and the role of antimicrobial and surgical therapy . Am J Med. 83:1987;653-660.
35. Mayer T.A., Bersoff-Matcha S., Murphy C., et al. Clinical presentation of inhalational anthrax following bioterrorism exposure. JAMA. 286:2001;2549-2553.
36. Ehlert K. Methicillin-resistance in Staphylococcus aureus - molecular basis, novel targets and antibiotic therapy. Curr Pharm Des. 5:1999;45-55.
37. 1998 Guidelines for treatment of sexually transmitted diseases. MMWR. 1998;47. (no. RR-1).
38. Ridgeway G.L. Quinolones in sexually transmitted diseases. Drugs. 58:(Suppl 2):1999;92-95.
39. Bebear C.M., Renaudin H., Boudjadja A., et al. In vitro activity of Bay 12-8039, a new fluoroquinolone against mycoplasmas. Antimicrob Agents Chemother. 42:1998;2304-2311.
40. Ahmed B.A., Tang A. Successful treatment of donovanosis with ciprofloxacin. Genitourin Med. 72:1996;73-74.
41. Lipsky B.A., Baker C.A. Fluoroquinolone toxicity profiles a review focusing on newer agents . Clin Infect Dis. 28:1999;352-364.
42. Lode H. Potential interactions of the extended-spectrum fluoroquinolones with the CNS. Drug Safety. 21:1999;123-135.
43. Ball P. Safety of the new fluoroquinolones compared with ciprofloxacin. J Chemother. 12:(Suppl 1):2000;8-11.
44. Carbon C. Comparison of side effects of levofloxacin versus other fluoroquinolones. Chemotherapy. 47:(Suppl 3):2001;9-14.
45. Mochizuki K., Higashide T., Torisaki M., et al. Effects of norfloxacin on the retina in rabbits. Graefes Arch Clin Exp Ophthalmol. 233:1995;173-180.
46. Ball P., Mandell L., Niki Y., et al. Comparative tolerability of the new fluoroquinolone antibacterials. Drug Safety. 21:1999;407-421.
47. Kushner J.M., Peckman H.J., Snyder C.R. Seizures associated with fluoroquinolones. Ann Pharacother. 2001;1194-1198.
48. Mulhall J.P., Bergmann L.S. Ciprofloxacin-induced acute psychosis. Urology. 46:1995;102-103.
49. McCue J.D., Zandt J.R. Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole. Am J Med. 90:1991;528-529.
50. Grassi L., Biancosino B., Agostini M., et al. Depression or hypoactive delirium? A report of ciprofloxacin-induced mental disorder in a patient with chronic obstructive pulmonary disease. Psychother Psychosom. 70:2001;58-59.
51. De Sarro A., De Sarro G. Adverse reactions to fluoroquinolones. An overview on mechanistic aspects. Curr Med Chem. 8:2001;371-384.
52. Schmuck G., Schurmann A., Schluter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother. 42:1998;1831-1836.
53. Van der Linden P.D., van der Lei J., Vlug A.E., Stricker B.H. Skin reactions to antibacterial agents in general practice. J Clin Epidemiol. 51:1998;703-708.
54. Campoli-Richards D.M., Monk J.P., Price A., et al. Ciprofloxacin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs. 35:1988;373-447.
55. Schacht P., Arcieri G., Hullmann R. Safety of oral ciprofloxacin. An update on clinical trial results. Am J Med. 87:1989;98S-102S.
56. Win A., Evers M.L., Chmel H. Stevens-Johnson syndrome presumably induced by ciprofloxacin. Int J Dermatol. 33:1994;512-514.
57. Wurtz R.M., Abrams D., Becker S., et al. Anaphylactoid drug reactions to ciprofloxacin and rifampicin in HIV-infected patients. Lancet. 1:1989;955-956.
58. Bircher A.J., Rutishauser M. Oral "desensitization" of maculopapular exanthema from ciprofloxacin. Allergy. 12:1997;1246-1248.
59. Dhar S., Sharma V.K. Fixed drug eruption due to ciprofloxacin. Br J Dermatol. 1:1996;156-158.
60. Livasy C.A., Kaplan A.M. Ciprofloxacin-induced toxic epidermal necrolysis a case report . Dermatology. 195:1997;173-175.
61. Lieu P.K., Tok S.C., Ismail N.H., Cheng H.H. Ciprofloxacin-induced cutaneous vasculitis. Allergy. 52:1997;593-594.
62. Shih D.J., Korbet S.M., Rydell J.J., Shwartz M.M. Renal vasculitis associated with ciprofloxacin. Am J Kidney Dis. 26:1995;516-519.
63. Pierfitte C., Royer R.J., Moore N., Begaud B. The link between sunshine and phototoxicity of sparfloxacin. Br J Clin Pharmacol. 49:2000;609-612.
64. Martinez L.J., Sik R.H., Chignell C.F. Fluoroquinolone antimicrobials singlet oxygen, superoxide and phototoxicity . Photochem Photobiol. 67:1998;399-403.
65. Fasani E., Barberis Negra F.F., et al. Photoinduced C-F bond cleavage in some fluorinated 7-amino-4-quinolone-3-carboxylic acids. J Org Chem. 64:1999;5388-5395.
66. Iannini P.B., Doddamani S., et al. Risk of torsade de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones. BMJ. 6:2001;46-47.
67. Stahlmann R., Lode H. Toxicity of quinolones. Drugs. 58:(Suppl 2):1999;37-42.
68. Stahlmann R., Schwabe R., Pfister K., et al. Supplementation with magnesium and tocopherol diminishes quinolone-induced chondrotoxicity in immature rats. Drugs. 58:(Suppl 2):1999;393-394.
69. Alghasham A.A., Nahata M.C. Clinical use of fluoroquino-lones in children. Ann Pharmacother. 34:2000;347-359.
70. Van der Linden P.D., van Puijenbroek E.P., Feenstra J., et al. Tendon disorders attributed to fluoroquinolones a study on 42 spontaneous reports in the period 1988 to 1998 . Arthritis Rheum. 45:2001;235-239.
71. Pierfitte C., Royer R.J. Tendon disorders with fluoroquinolones. Therapie. 51:1996;419-420.
72. Nakamura H., Ohtsuka T., Enomoto H., et al. Effect of levofloxacin on theophylline clearance during theophylline and clarithromycin combination therapy. Ann Pharmacother. 35:2001;691-693.
73. Mahr G., Sorgel F., Granneman G.R., et al. Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. Clin Pharmacokinet. 22:(Suppl 1):1992;90-97.
74. Polk R.E. Drug-drug interactions with ciprofloxacin and other fluoroquinolones. Am J Med. 87:1989;76S-81S.